title: Posttransplantation diabetus mellitus under calcineurin inhibitor.
abstract: BACKGROUND
  The development of postransplantation diabetes mellitus (PTDM) is a serious complication of kidney transplantation. PTDM has a major impact on quality of life decreasing rates of patient and graft survival. It is well known that some currently used immunosuppressants are diabetogenic. Greater diabetogenicity of FK-506 has been reported in multicenter trials. We initiated a study of conversion from tacrolimus (FK-506) to cyclosporine (CsA) among kidney allograft recipients presenting with PTDM to evaluate whether this maneuver would ameliorate a diabetic state.
  
  
  METHODS
  This analysis of 20 adult, renal allograft recipients presenting with PTDM assumed the need for insulin therapy or oral hypoglycemics before and after conversion of the immunosuppressive regimen. The criteria for evaluating the outcome were as follows: dose reduction of insulin or oral hypoglycemic agents, adequacy of glucose control, C-peptide levels, and insulin concentration.
  
  
  RESULTS
  During the follow-up, we observed an improvement in the control of blood glucose in the converted group. In 13 patients, satisfactory glucose control was obtained without insulin or any other agent. In 3 patients a significant dose reduction of required insulin was possible. In another 2 patients who were insulin-dependent, the switch to oral hypoglycemic treatment was clinically possible after conversion. After conversion we observed significantly lowered fasting blood glucose levels and increased C-peptide levels.
  
  
  CONCLUSIONS
  The conversion from a tacrolimus to a CsA-based immunosuppressive regimen resulted in better glucose metabolism. We demonstrated a positive effect of conversion on the diabetic state of patients with PTDM.
authors.affiliation: Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Wyzgal
authors.forename: U
authors.initials: U
authors.lastname: Oldakowska-Jedynak
authors.forename: L
authors.initials: L
authors.lastname: Paczek
authors.forename: M
authors.initials: M
authors.lastname: Michalska
authors.forename: J
authors.initials: J
authors.lastname: Ziolkowski
authors.forename: L
authors.initials: L
authors.lastname: Soluch
authors.forename: D
authors.initials: D
authors.lastname: Zygier
authors.forename: J
authors.initials: J
authors.lastname: Sanko-Resmer
authors.forename: L
authors.initials: L
authors.lastname: Gradowska
authors.forename: M
authors.initials: M
authors.lastname: Niewczas
authors.forename: Z
authors.initials: Z
authors.lastname: Galazka
authors.forename: M
authors.initials: M
authors.lastname: Pacholczyk
authors.forename: M
authors.initials: M
authors.lastname: Durlik
mesh_terms: D000328:Adult; D002096:C-Peptide / Q000097:blood; D003920:Diabetes Mellitus / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D016019:Survival Analysis; D013997:Time Factors
chemical_list: D002096:C-Peptide; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds